Biocom California Stands Firm Against Most Favored Nation Rule

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Nov 20, 2020 10:50 pm
SAN DIEGO & LOS ANGELES & SOUTH SAN FRANCISCO, Calif. -- 

Biocom California, the association representing the California life science industry, issued the following statement in response to the release of the Most Favored Nation (MFN) Model by the Centers for Medicare and Medicaid Services (CMS) today. This statement may be attributed to Joe Panetta, president and CEO of Biocom California:

“The Trump administration has decided to proceed with a deeply-flawed plan to impose arbitrary foreign price controls on drugs and biologics that are administered in physicians’ offices and treat some of our country’s sickest and most vulnerable patients. The rule came out today, despite repeated warnings by the biomedical research community that such a policy would hurt innovation and reduce patients’ access to lifesaving products currently available in the U.S.

“Biocom California is deeply disappointed that this model was released as an interim final rule, as it will disproportionally affect small companies that rely on a predictable and steady environment. It makes sweeping changes across all states, has an almost immediate implementation date and had no input from stakeholders for this specific incarnation. This model will undeniably reduce long-term investments in research and hamper the development of new treatments and cures. California, which is one of the world’s leaders in biomedical innovation, would be among the first to suffer.

“Our patients, our economy and our whole nation are looking to the biotechnology industry for hope during our most deadly national pandemic in recent history. Now is not the time to slow down the industry that is working around the clock to develop the vaccines and therapeutics needed to combat COVID-19. Biocom California stands firm against this proposal and welcomes policies that would instead expand patients’ access to innovative medicines and reduce out-of-pocket costs.”

About Biocom California

Biocom California is the leader and advocate for California’s life science sector. We work on behalf of more than 1,300 members to drive public policy, build an enviable network of industry leaders, create access to capital, introduce cutting-edge STEM education programs, and create robust value-driven purchasing programs.

Founded in 1995 in San Diego, Biocom California provides the strongest public voice to research institutions and companies that fuel the local and state-wide economy. Our goal is simple: to help our members produce novel solutions that improve the human condition. In addition to our San Diego headquarters, Biocom California operates core offices in Los Angeles and the San Francisco Bay Area, satellite offices in Washington, D.C. and Tokyo, and has a continuous staff presence in Sacramento. Our broad membership benefits apply to biotechnology, pharmaceutical, medical device, genomics and diagnostics companies of all sizes, as well as to research universities and institutes, clinical research organizations, investors and service providers.

For more information on Biocom California, please visit our website at www.biocom.org. Connect with us on LinkedIn, Facebook, and Twitter (@BIOCOMCA).

Carolyn Hawley
Canale Communications
[email protected]
619-849-5382

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).